Is metabolic syndrome a condition independent of prediabetes and type 2 diabetes mellitus? A report from Turkey

Endocrine Journal

Volumn 54, Issue 5, 2007, Pages 745-750

  Uzunlulu, Mehmet ^a,b   Oguz, Aytekin ^a  

^a GOZTEPE TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Altaycesme Mahallesi   (Turkey)

Author keywords

Metabolic syndrome; Prediabetes; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; LIPID;

ADULT; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE; DEMOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; RISK FACTOR; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; TURKEY (REPUBLIC); WAIST CIRCUMFERENCE; BLOOD; COMPARATIVE STUDY; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; INCIDENCE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INCIDENCE; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREDIABETIC STATE; RISK FACTORS; TURKEY;

EID: 40649095027     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K07-036     Document Type: Article

References (23)

1. Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365: 1415-1428.
2. DeFronzo RA, Ferrannini E (1991) Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14: 173-194.
3. Igarashi M, Hirata A, Kadomoto Y, Tominaga M (2006) Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes. Endocr J 53: 493-501.
4. Miwa S, Watada H, Omura C, Takayanagi N, Nishiyama K, Tanaka Y, Onuma T, Kawamori R (2005) Antioxidative effect of fluvastatin in hyperlipidemic type 2 diabetic patients. Endocr J 52: 259-264.
5. Kahn R, Buse J, Ferrannini E, Stern M (2005) The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28: 2289-2304.
6. Alexander CM, Landsman PB, Teutsch SM, Haffner SM (2003) NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52: 1210-1214.
7. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow-up report on the diagnosis of diabetes mellitus (2003). Diabetes Care 26: 3160-3167.
8. World Health Organization. Diabetes Mellitus: Report of a WHO Study Group. Technical Report Series 727. Geneva: WHO, 1985.
9. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. (Adult Treatment Panel III) (2001) JAMA 285: 2486-2497.
10. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J (2005) The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 12: 295-300.
11. Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults. JAMA 287: 356-359.
12. Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, Morris R, Zavaroni I, van Dam R, Feskins E, Gabriel R, Diet M, Nilsson P, Hedblad B (2002) European Group for the Study of Insulin Resistance (EGIR): Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabete Metab 28: 364-376.
13. Enkhmaa B, Shiwaku K, Anuurad E, Nogi A, Kitajima K, Yamasaki M, Oyunsuren T, Yamane Y (2005) Prevalence of the metabolic syndrome using the Third Report of the National Cholesterol Educational Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III) and the modified ATP III definitions for Japanese and Mongolian. Clin Chim Acta 352: 105-113.
14. Lee WY, Park JS, Noh SY, Rhee EJ, Kim SW, Zimmet PZ (2004) Prevalence of the metabolic syndrome among 40,698 Korean metropolitan subjects. Diabetes Res Clin Pract 65: 143-149.
15. Arai H, Yamamoto A, Matsuzawa Y, Saito Y, Yamada N, Oikawa S, Mabuchi H, Teramoto T, Sasaki J, Nakaya N, Itakura H, Ishikawa Y, Ouchi Y, Horibe H, Shirahashi N, Kita T (2006) Prevalence of metabolic syndrome in the general Japanese population in 2000. J Atheroscler Thromb 13: 202-208.
16. Tan CE, Ma S, Wai D, Chew SK, Tai ES (2004) Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 27: 1182-1186.
17. Kozan O, Oguz A, Abaci A, Erol C, Ongen Z, Temizhan A, Celik S (2007) Prevalence of the metabolic syndrome among Turkish adults. Eur J Clin Nutr 61: 548-553.
18. Onat A, Ceyhan K, Basar O, Erer B, Toprak S, Sansoy V (2002) Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels - a prospective and cross-sectional evaluation. Atherosclerosis 165: 285-292.
19. International Diabetes Federation. Worldwide definition of the metabolic syndrome. Available at: http://www.idf.org/webdata/does/IDF-Meta-syndrome- definition. pdf. Accessed August 24, 2005.
20. World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Geneva, World Health Org., 1999.
21. Bloomgarden ZT (2003) American Association of Clinical Endocrinologists (AACE) Consensus Conference on the Insulin Resistance Syndrome, 25-26 August 2002, Washington, DC. Diabetes Care 26: 1297-1303.
22. Reaven GM (1988) Role of insulin resistance in human disease. Diabetes 37: 1595-1607.
23. Unwin N, Shaw J, Zimmet P, Alberti K (2002) Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 19: 708-723.